GSK Wins FDA Accelerated Approval for Lung Cancer Drug Nelkarmi
GSK received accelerated approval from the U.S. Food and Drug Administration for Nelkarmi in advanced ALK-positive lung cancer, clearing the company to launch the medicine in the United States. The drug came to GSK through its acquisition of Nuvalent.
The company is working to build a franchise in lung cancer, which is the leading cause of cancer death, and the approval adds to its oncology portfolio.
GSK reported revenue of 32.67 billion GBP in fiscal 2025. Its next earnings date is scheduled for Feb 3, 2027.
Important questions to consider
The FDA granted accelerated approval for Nelkarmi in advanced ALK-positive lung cancer. The decision allows GSK to begin selling the medicine in the U.S.
Nelkarmi was obtained through GSK's acquisition of Nuvalent. The approval therefore adds an acquired asset to the company's oncology lineup.
Lung cancer is the leading cause of cancer death, and GSK is trying to establish a franchise in the disease. The company's revenue was 32.67 billion GBP in fiscal 2025, before this launch.